Trastuzumab rezetecan for her2-low breast cancer with visceral crisis
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new antibody-drug combination called trastuzumab rezetecan (SHR-A1811) in people with a specific type of breast cancer (HER2-low) that has spread and is causing serious organ problems (visceral crisis). The goal is to see if this treatment can help when organs like the liver or lungs are rapidly failing due to the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- Your breast cancer is HER2-low, has spread, and cannot be removed by surgery.
- You have a 'visceral crisis' meaning your cancer is causing severe organ problems (like rapid liver or lung failure).
- You have had no more than 1 round of chemotherapy for advanced disease.
- Your blood counts are adequate (neutrophils, platelets, and hemoglobin levels are within a safe range).
- You have not been treated with another antibody-drug conjugate (ADC) for breast cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, trastuzumab rezetecan, for women with breast cancer that has come back or spread and cannot be removed by surgery. It's for those who haven't had chemotherapy for advanced disease but have tried hormone therapy and it stopped working.
This Phase 2 study tests whether adding trastuzumab (a targeted antibody) given with chemo and extra drugs can better treat certain HER2-positive, locally advanced or inflammatory breast cancers. It may help by improving cancer control in people who have not had prior anti-cancer treatment for their breast cancer.
This trial tests a combination of three drugs (trastuzumab rezetecan, adebrelimab, and lenvatinib) as a first treatment for people with advanced HER2-positive or HER2-low bile duct or gallbladder cancer. The goal is to see if this combination helps shrink or control the cancer.
This trial tests two new antibody-based drugs (trastuzumab rezetecan and trastuzumab deruxtecan) designed to treat advanced breast cancer that has spread or cannot be removed with surgery. These drugs target HER2, a protein found on certain cancer cells, and may help patients whose cancer has progressed after previous treatment with trastuzumab and chemotherapy.
This trial tests a new drug, Trastuzumab-rezetecan, in people with breast cancer that has a certain amount of a protein called HER2. It aims to see if the drug works and is safe for patients who are able to receive it before or after surgery, or for those whose cancer has spread and has been treated before.
This study tests a new drug (trastuzumab rezetecan) for advanced solid tumors that have a protein called HER2 on their surface. The drug combines an antibody that targets HER2 with a chemotherapy component. It's designed for cancers that have grown despite prior treatment or have no good alternatives.
Hear when a new HER2-Low Unresectable/Metastatic Breast Cancer Complicated With Visceral Crisis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.